ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Lexeo Therapeutics (LXEO)
Lexeo Therapeutics stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$2.86▲ +5.93%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
46%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Lexeo Therapeutics in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Lexeo Therapeutics
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Lexeo Therapeutics a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $2.45 and $3.21; in 9 out of 10, between $1.93 and $4.07. Estimated annual volatility is 76%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $290M
- 52-week high
- $10.99
- 52-week low
- $2.55
- Revenue (12 months)
- $0.0M
- Return on equity
- -46.8%
- Free cash flow (12 months)
- $-58.8M
- Beta
- 1.50
What this means
ATLAS does not publish a fair value for LXEO right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks LXEO has traded between $2.55 and $10.99. Today it is 74.0% below that high and 12% above its low.
Its beta is 1.50: it tends to move more than the market, both up and down.
About the company
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company focused on developing gene therapy candidates for hereditary and acquired diseases with high unmet medical need.
Want to see everything about Lexeo Therapeutics?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Lexeo Therapeutics do?
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company focused on developing gene therapy candidates for hereditary and acquired diseases with high unmet medical need.
What is the chance LXEO goes up next month?
46%: close to a coin flip. In half of the simulated outcomes, LXEO ends the month between $2.45 and $3.21.
How big is Lexeo Therapeutics and what is its P/E ratio?
Lexeo Therapeutics's market capitalization is $290M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is LXEO?
ATLAS estimates annual volatility at 76%. In a typical month, half of the outcomes end between $2.45 and $3.21.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer